ArticleClinics and research in hepatology and gastroenterology2019

Incretin-based treatment in type 2 diabetes mellitus and risk of cholangiocarcinoma: Is it only adverse drug effect?

Gian Maria Barbato et al.PubMed ↗Publisher ↗

No numbers read from the abstract.